KRYS
Price
$143.08
Change
+$1.73 (+1.22%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
4.02B
39 days until earnings call
ZLDPF
Price
$57.75
Change
+$0.45 (+0.79%)
Updated
Jul 1 closing price
Capitalization
4.09B
Interact to see
Advertisement

KRYS vs ZLDPF

Header iconKRYS vs ZLDPF Comparison
Open Charts KRYS vs ZLDPFBanner chart's image
Krystal Biotech
Price$143.08
Change+$1.73 (+1.22%)
Volume$16.25K
Capitalization4.02B
Zealand Pharma A/S
Price$57.75
Change+$0.45 (+0.79%)
Volume$741
Capitalization4.09B
KRYS vs ZLDPF Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. ZLDPF commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and ZLDPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (KRYS: $141.36 vs. ZLDPF: $57.75)
Brand notoriety: KRYS and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 55% vs. ZLDPF: 89%
Market capitalization -- KRYS: $4.02B vs. ZLDPF: $4.09B
KRYS [@Biotechnology] is valued at $4.02B. ZLDPF’s [@Biotechnology] market capitalization is $4.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than ZLDPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 6 TA indicator(s) are bullish while ZLDPF’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 6 bullish, 3 bearish.
  • ZLDPF’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both KRYS and ZLDPF are a good buy in the short-term.

Price Growth

KRYS (@Biotechnology) experienced а -0.80% price change this week, while ZLDPF (@Biotechnology) price change was +3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($4.09B) and KRYS($4.02B) have the same market capitalization . KRYS YTD gains are higher at: -9.766 vs. ZLDPF (-43.581). KRYS has higher annual earnings (EBITDA): 140M vs. ZLDPF (-1.13B). ZLDPF has more cash in the bank: 8.54B vs. KRYS (617M). KRYS has less debt than ZLDPF: KRYS (9.66M) vs ZLDPF (395M). KRYS has higher revenues than ZLDPF: KRYS (333M) vs ZLDPF (55.7M).
KRYSZLDPFKRYS / ZLDPF
Capitalization4.02B4.09B98%
EBITDA140M-1.13B-12%
Gain YTD-9.766-43.58122%
P/E Ratio33.34N/A-
Revenue333M55.7M598%
Total Cash617M8.54B7%
Total Debt9.66M395M2%
FUNDAMENTALS RATINGS
KRYS vs ZLDPF: Fundamental Ratings
KRYS
ZLDPF
OUTLOOK RATING
1..100
2168
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
3979
SMR RATING
1..100
5794
PRICE GROWTH RATING
1..100
6290
P/E GROWTH RATING
1..100
976
SEASONALITY SCORE
1..100
n/a8

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (70) in the Pharmaceuticals Major industry is in the same range as ZLDPF (76) in the null industry. This means that KRYS’s stock grew similarly to ZLDPF’s over the last 12 months.

KRYS's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZLDPF (79) in the null industry. This means that KRYS’s stock grew somewhat faster than ZLDPF’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZLDPF (94) in the null industry. This means that KRYS’s stock grew somewhat faster than ZLDPF’s over the last 12 months.

KRYS's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as ZLDPF (90) in the null industry. This means that KRYS’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (6) in the null industry is significantly better than the same rating for KRYS (97) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSZLDPF
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMIX26.32N/A
N/A
Goldman Sachs Emerging Markets Eq Instl
DIISX22.86N/A
N/A
BNY Mellon International Stock Index Inv
LZUSX17.22N/A
N/A
Lazard US Equity Focus Instl
APGYX116.64N/A
N/A
AB Large Cap Growth Advisor
MWOFX64.36N/A
N/A
MFS Global Growth A

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+1.69%
ACLX - KRYS
55%
Loosely correlated
+2.55%
CRNX - KRYS
55%
Loosely correlated
+2.40%
XNCR - KRYS
54%
Loosely correlated
+2.85%
IDYA - KRYS
54%
Loosely correlated
+3.79%
CGON - KRYS
54%
Loosely correlated
+1.25%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with KRYS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
N/A
KRYS - ZLDPF
46%
Loosely correlated
+1.69%
CLDX - ZLDPF
30%
Poorly correlated
+8.65%
NERV - ZLDPF
22%
Poorly correlated
+3.59%
SNDX - ZLDPF
22%
Poorly correlated
+2.04%
MIST - ZLDPF
22%
Poorly correlated
+1.86%
More